ReviewInternational journal of hematology2014
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
Review in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02782351 (Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19), which is not on this map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- The growing world of CAR T cell trials: a systematic review.Cancer immunology, immunotherapy : CII · 2016Pooled it
- Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.Balkan medical journal · 2025Review
- Prospects for γδ T cells and chimeric antigen receptor γδ T cells in cancer immunotherapy.Frontiers in immunology · 2025Review
- The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseases.Protein & cell · 2024Article
- Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.Discover oncology · 2024Review
- Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers.World journal of clinical oncology · 2024Review
- CAR T therapies in multiple myeloma: unleashing the future.Cancer gene therapy · 2024Review
- Immune-reactive tumor organoids system to determine the effects of microbial metabolites on cancer immunity and immunotherapies.Frontiers in microbiomes · 2024Article
- The research status and prospects of MUC1 in immunology.Human vaccines & immunotherapeutics · 2023Article
- Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?Frontiers in immunology · 2023Review
- Emerging CAR T Cell Strategies for the Treatment of AML.Cancers · 2022Review
- Extremely High-Throughput Parallel Microfluidic Vortex-Actuated Cell Sorting.Micromachines · 2021Article
- The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy.Proceedings. Biological sciences · 2021Article
- Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review.Translational cancer research · 2021Review
- Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.Cancers · 2021Article
- Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.Frontiers in genetics · 2021Article
- CART Cell Toxicities: New Insight into Mechanisms and Management.Clinical hematology international · 2020Article
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.Cancers · 2020Review
- Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.Immunotherapy · 2020Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin's lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.